Metabolomics profiles in acute-on-chronic liver failure: Unveiling pathogenesis and predicting progression

Acute-on-chronic liver failure (ACLF) usually develops based on acute decompensation (AD) of cirrhosis and is characterized by intense systemic inflammation, multiple organ failure, and high short-term mortality. Validated biomarkers for the diagnosis and prognosis of ACLF remain to be clarified. Me...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 953297
Main Authors Liu, Guofeng, Wang, Xiaoze, Fan, Xiaoli, Luo, Xuefeng
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 19.08.2022
Subjects
ACLF (acute-on-chronic liver failure)
metabolites
metabolomics
OxPhos
Pharmacology
systemic inflammation
Online AccessGet full text

Cover

More Information
Summary:Acute-on-chronic liver failure (ACLF) usually develops based on acute decompensation (AD) of cirrhosis and is characterized by intense systemic inflammation, multiple organ failure, and high short-term mortality. Validated biomarkers for the diagnosis and prognosis of ACLF remain to be clarified. Metabolomics is an emerging method used to measure low-molecular-weight metabolites and is currently frequently implemented to understand pathophysiological processes involved in disease progression, as well as to search for new diagnostic or prognostic biomarkers of various disorders. The characterization of metabolites in ACLF has recently been described via metabolomics. The role of metabolites in the pathogenesis of ACLF deserves further investigation and improvement and could be the basis for the development of new diagnostic and therapeutic strategies. In this review, we focused on the contributions of metabolomics on uncovering metabolic profiles in patients with ACLF, the key metabolic pathways that are involved in the progression of ACLF, and the potential metabolite-associated therapeutic targets for ACLF.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology
Edited by: Pedro Miguel Rodrigues, Biodonostia Health Research Institute (IIS Biodonostia), Spain
These authors have contributed equally to this work and share first authorship
Elisa Pinto, University of Padua, Italy
Reviewed by: André Simão, Research Institute for Medicines (iMed.ULisboa), Portugal
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.953297